United States 119th Congress Status: In Committee Bipartisan · 4 D · 4 R cosponsors

HR 9169 — PKD Cures Act

Last action — Referred to the House Committee on Energy and Commerce.

  1. ✓
    Introduced
  2. 2
    In Committee
  3. 3
    Passed House
  4. 4
    Passed Senate
  5. 5
    To Executive
  6. 6
    Enacted

This bill is in committee in the House. Introduced June 04, 2026. It must pass committee before a floor vote.

Next likely step: a committee vote, then a floor vote in the House.

Odds of enactment

Low chance

Based on the sponsor, cosponsors, and committee posture, this bill has a low chance of becoming law.

Upgrade to see the exact probability and what's driving it.

A statistical estimate from our own model of past outcomes — an insight, not a guarantee. Policymaking is volatile.

Prognosis

Advancing 42% · moderate confidence

  • In Committee

    Current position in the legislative process.

  • 8 sponsors

    1 primary, 7 co-sponsors signed on.

  • Bipartisan support

    Sponsored across 2 parties (4 D · 4 R) — cross-party backing.

Based on stage, sponsorship breadth, committee status, recorded votes, and cross-state momentum — a description of the observable signals, not a prediction.

In plain language

The bill addresses research and treatment for polycystic kidney disease (PKD).

This legislation focuses on improving research and treatment options for polycystic kidney disease. It aims to enhance understanding and care for individuals affected by this condition.

What this means for you
  • Healthcare: This means healthcare professionals may see new research and treatment options for patients with PKD.

Bill Text

How this bill changes current law

2 changes Share ↗

Compared against current U.S. Code AI-generated reading aid — verify against the official bill.

The bill adds new sections to the law to specifically enhance research and innovation regarding polycystic kidney disease within the National Institute of Diabetes and Digestive and Kidney Diseases.

  • 42 U.S.C. § 285c

    SEC. 434B. EXPANSION OF NIH RESEARCH ON POLYCYSTIC KIDNEY DISEASE. (a) Research Focus.--The Director of the Institute shall expand and intensify research activities regarding polycystic kidney disease (in this section referred to as `PKD'), including-- (1) basic research to understand the genetic and molecular mechanisms of PKD; (2) translational research to identify biomarkers and potential therapeutic targets; and (3) clinical research to evaluate the safety and efficacy of new and existing treatments. (b) Collaboration.--In implementing the requirements of subsection (a), the Director of the Institute shall-- (1) collaborate with other Federal agencies, academic institutions, and private sector stakeholders to accelerate the development of treatments and cures; and (2) support training programs to cultivate a workforce of researchers and clinicians specializing in PKD. (c) Priority.--In implementing the requirements of subsection (a), the Director of the Institute shall prioritize research proposals that demonstrate a clear potential to advance understanding and treatment of PKD.

    This adds a mandate for the National Institute of Diabetes and Digestive and Kidney Diseases to focus on researching polycystic kidney disease.

  • 42 U.S.C. § 285c

    SEC. 434C. DEVELOPMENT OF COMPREHENSIVE PKD ROADMAP. (a) In General.--The Director of NIH shall establish a working group to develop a comprehensive roadmap for polycystic kidney disease (in this section referred to as `PKD') research and innovation. (b) Membership.--The Director of NIH shall appoint the members of the working group, who shall be-- (1) experts in nephrology, human genetics, or molecular and cellular biology with expertise in the mechanistic pathways of PKD; (2) representatives of PKD patient advocacy organizations; or (3) such other stakeholders as the Director determines appropriate. (c) Responsibilities.--In developing the comprehensive roadmap referred to in subsection (a), the working group shall-- (1) identify research gaps and priorities; (2) recommend strategies to enhance collaboration between the public and private sectors; (3) propose timelines and benchmarks for achieving key milestones in PKD innovation; and (4) develop a plan for integrating new technologies, such as artificial intelligence and precision medicine, into PKD research and care. (d) Report.--Not later than 24 months after the date of enactment of this section, the working group shall submit to Congress a report detailing the findings and recommendations of the working group, including the comprehensive roadmap referred to in subsection (a).

    This establishes a working group to create a strategic plan for advancing research and innovation in polycystic kidney disease.

Action History

  1. Introduced in House

  2. Introduced in House

  3. Referred to the House Committee on Energy and Commerce.

Sponsors

Sponsorship breakdown

Export CSV (upgrade) →

1 sponsors · 7 co-sponsors · 539 not signed on

Sponsors (1)

Co-sponsors (7)

Not signed on (539)

539 members have not signed on to this bill.

Show all 539 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Subjects

healthcare health-insurance
Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

Who sponsors HR 9169?
HR 9169 is sponsored by Miller, Carol D. (Republican), Cleaver, Emanuel (Democratic), Bacon, Don (Republican), Wilson, Joe (Republican), Van Drew, Jefferson (Republican), Davids, Sharice (Democratic), DelBene, Suzan K. (Democratic), and Wasserman Schultz, Debbie (Democratic).
What is the current status of HR 9169?
This bill is in committee in the House. Introduced June 04, 2026. It must pass committee before a floor vote.
Where can I track HR 9169?
Track HR 9169 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on HR 9169

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Find my representatives → Run a campaign

Stay ahead of HR 9169

Last checked for changes 3 months ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →